{"product_id":"bugs-as-drugs-isbn-9781555819699","title":"Bugs as Drugs","description":"\u003cp\u003e\u003cb\u003eExamining the enormous potential of microbiome manipulation to improve health\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAssociations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. \u003ci\u003eBugs as Drugs\u003c\/i\u003e provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease.\u003c\/p\u003e \u003cp\u003eIn \u003ci\u003eBugs as Drugs\u003c\/i\u003e, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eHow well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response.\u003c\/li\u003e \u003cli\u003eThe use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage.\u003c\/li\u003e \u003cli\u003eThe association of specific microbiota composition with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis.\u003c\/li\u003e \u003cli\u003eFecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes.\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eBecause systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted.\u003cbr\u003e\u003cbr\u003e\u003c\/p\u003e \u003cp\u003eIf you are looking for online access to the latest clinical microbiology content, please visit \u003ca href=\"http:\/\/www.wiley.com\/learn\/clinmicronow\"\u003ewww.wiley.com\/learn\/clinmicronow\u003c\/a\u003e.\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e \u003cp\u003eContributors vii\u003c\/p\u003e \u003cp\u003eAbout the Editors xii\u003c\/p\u003e \u003cp\u003ePreface xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eA. Traditional Probiotic Approaches\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Biochemical Features of Beneficial Microbes: Foundations for Therapeutic Microbiology 3\u003cbr\u003e\u003ci\u003eMelinda A. Engevik and James Versalovic\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 The Genomic Basis of Lactobacilli as Health-Promoting Organisms 49\u003cbr\u003e\u003ci\u003eElisa Salvetti and Paul W. O’Toole\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Bifidobacteria and Their Health-Promoting Effects 73\u003cbr\u003e\u003ci\u003eClaudio Hidalgo-Cantabrana, Susana Delgado, Lorena Ruiz, Patricia Ruas-Madiedo, Borja Sánchez, and Abelardo Margolles\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eB. Next-Generation Bacteriotherapy: Opportunities in Chronic Diseases\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4 Microbial Interactions and Interventions in Colorectal Cancer 101\u003cbr\u003e\u003ci\u003eTerence Van Raay and Emma Allen-Vercoe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Microbial Impact on Host Metabolism: Opportunities for Novel Treatments of Nutritional Disorders? 131\u003cbr\u003e\u003ci\u003eHubert Plovier and Patrice D. Cani\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Therapeutic Opportunities in the Vaginal Microbiome 149\u003cbr\u003e\u003ci\u003eGregor Reid\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 Lung Microbiota and Its Impact on the Mucosal Immune Phenotype 161\u003cbr\u003e\u003ci\u003eBenjamin G. Wu and Leopoldo N. Segal\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Microbiota, Liver Diseases, and Alcohol 187\u003cbr\u003e\u003ci\u003eAnne-Marie Cassard, Philippe Gérard, and Gabriel Perlemuter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 The Potential of Probiotics as a Therapy for Osteoporosis 213\u003cbr\u003e\u003ci\u003eFraser L. Collins, Naiomy D. Rios-Arce, Jonathan D. Schepper, Narayanan Parameswaran, and Laura R. McCabe\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Ecological Therapeutic Opportunities for Oral Diseases 235\u003cbr\u003e\u003ci\u003eAnilei Hoare, Philip D. Marsh, and Patricia I. Diaz\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eC. Control of Infectious Disease by Microbes\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11 Control of Clostridium difficile Infection by Defined Microbial Communities 269\u003cbr\u003e\u003ci\u003eJames Collins and Jennifer M. Auchtung\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 Fecal Microbiota Transplantation: Therapeutic Potential for a Multitude of Diseases beyond Clostridium difficile 291\u003cbr\u003e\u003ci\u003eGuido J. Bakker and Max Nieuwdorp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Enterococci and Their Interactions with the Intestinal Microbiome 309\u003cbr\u003e\u003ci\u003eKrista Dubin and Eric G. Pamer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eD. Next-Generation Microbial Therapeutics: Tools and Regulation\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e14 Engineering Diagnostic and Therapeutic Gut Bacteria 333\u003cbr\u003e\u003ci\u003eBrian P. Landry and Jeffrey J. Tabor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Use of Traditional and Genetically Modified Probiotics in Human Health: What Does the Future Hold? 363\u003cbr\u003e\u003ci\u003eLuis G. Bermúdez-Humarán and Philippe Langella\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Genetic Tools for the Enhancement of Probiotic Properties 371\u003cbr\u003e\u003ci\u003eLaura Ortiz-Velez and Robert Britton\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 Genome Editing of Food-Grade Lactobacilli to Develop Therapeutic Probiotics 389\u003cbr\u003e\u003ci\u003eJan-Peter van Pijkeren and Rodolphe Barrangou\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18 United States Regulatory Considerations for Development of Live Biotherapeutic Products as Drugs 409\u003cbr\u003e\u003ci\u003eSheila M. Dreher-Resnick, Scott Stibitz, and Paul E. Carlson, Jr.\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eE. Indirect Strategies to Target Microbiome Function for Health\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19 Bacteriophage Clinical Use as Antibacterial “Drugs”: Utility and Precedent 419\u003cbr\u003e\u003ci\u003eStephen T. Abedon\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20 Modulation of the Gastrointestinal Microbiome with Nondigestible Fermentable Carbohydrates to Improve Human Health 453\u003cbr\u003e\u003ci\u003eEdward C. Deehan, Rebbeca M. Duar, Anissa M. Armet, Maria Elisa Perez-Muñoz, Mingliang Jin, and Jens Walter\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 485\u003c\/p\u003e   \u003cp class=\"MsoNormal\"\u003e\u003cspan lang=\"EN-CA\"\u003eBecause microbiome research studies are being published at an unprecedented rate, a reliable book that reviews the seminal work and knowledge gaps in this field is pressingly needed. In \u003ci\u003eBugs as Drugs: Therapeutic Microbes for the Prevention and Treatment of Disease\u003c\/i\u003e, the authors address major themes in microbiome research, particularly focusing on therapeutic applications.\u003c\/span\u003e  \u003c\/p\u003e\u003cp class=\"MsoNormal\"\u003e\u003cspan lang=\"EN-CA\"\u003eThis ~500-page volume, edited by Robert A. Britton and Patrice D. Cani, comprises 5 main sections of varying scope and length. The introductory section reviews pathways used by commensals, particularly Lactobacilli and Bifidobacteria spp., to benefit the host. The first chapter is particularly impressive, providing a thorough and well-cited overview of the various microbial metabolites and how they influence the host.\u003c\/span\u003e  \u003c\/p\u003e\u003cp class=\"MsoNormal\"\u003e\u003cspan lang=\"EN-CA\"\u003e...Overall, this book is a commendable and timely volume of well-sourced reviews written by experts in the field well organized into broad research themes. This work will serve as a helpful resource for both scientists and clinicians interested in using microbes for therapeutic applications.\u003c\/span\u003e  \u003c\/p\u003e\u003cp class=\"MsoNormal\"\u003e\u003cb\u003e\u003cspan lang=\"EN-CA\"\u003e-Excerpted from the full review in \u003ci\u003eEmerging Infectious Diseases, Vol. 25, No.7, Books and Media\u003c\/i\u003e\u003co:p\u003e\u003c\/o:p\u003e\u003c\/span\u003e\u003c\/b\u003e  \u003c\/p\u003e\u003cp class=\"MsoNormal\"\u003e\u003cspan lang=\"EN-CA\"\u003e \u003cp\u003e\u003cb\u003eRobert A. Britton\u003c\/b\u003e, Micalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePatrice D. Cani\u003c\/b\u003e, Baylor College of Medicine, Molecular Virology and Microbiology, Houston, Texas.\u003c\/p\u003e  \u003cp\u003e\u003cb\u003eBugs as Drugs\u003c\/b\u003e \u003c\/p\u003e\n\u003cp\u003eFirst Edition \u003c\/p\u003e\n\u003cp\u003e\u003ci\u003eExamining the enormous potential of microbiome manipulation to improve health.\u003c\/i\u003e  \u003c\/p\u003e\n\u003cp\u003eAssociations between the composition of the intestinal microbiome and many human diseases, including inflammatory bowel disease, cardiovascular disease, metabolic disorders, and cancer, have been elegantly described in the past decade. Now, whole-genome sequencing, bioinformatics, and precision gene-editing techniques are being combined with centuries-old therapies, such as fecal microbiota transplantation, to translate current research into new diagnostics and therapeutics to treat complex diseases. \u003ci\u003eBugs as Drugs\u003c\/i\u003e provides a much-needed overview of microbes in therapies and will serve as an excellent resource for scientists and clinicians as they carry out research and clinical studies on investigating the roles the microbiota plays in health and disease.  \u003c\/p\u003e\n\u003cp\u003eIn \u003ci\u003eBugs as Drugs\u003c\/i\u003e, editors Robert A. Britton and Patrice D. Cani have assembled a fascinating collection of reviews that chart the history, current efforts, and future prospects of using microorganisms to fight disease and improve health. Sections cover traditional uses of probiotics, next-generation microbial therapeutics, controlling infectious diseases, and indirect strategies for manipulating the host microbiome. Topics presented include: \u003c\/p\u003e\n\u003cul\u003e \u003cli\u003eHow well-established probiotics support and improve host health by improving the composition of the intestinal microbiota of the host and by modulating the host immune response.\u003c\/li\u003e \u003cli\u003eThe use of gene editing and recombinant DNA techniques to create tailored probiotics and to characterize next-generation beneficial microbes. For example, engineering that improves the anti-inflammatory profile of probiotics can reduce the number of colonic polyps formed, and lactobacilli can be transformed into targeted delivery systems carrying therapeutic proteins or bioengineered bacteriophage.\u003c\/li\u003e \u003cli\u003eThe association of specific microbiota composition  with colorectal cancer, liver diseases, osteoporosis, and inflammatory bowel disease. The gut microbiota has been proposed to serve as an organ involved in regulation of inflammation, immune function, and energy homeostasis.\u003c\/li\u003e \u003cli\u003eFecal microbiota transplantation as a promising treatment for numerous diseases beyond C. difficile infection. Practical considerations for using fecal microbiota transplantation are provided, while it is acknowledged that more high-quality evidence is needed to ascertain the importance of strain specificity in positive treatment outcomes.\u003c\/li\u003e \u003c\/ul\u003e  \u003cp\u003eBecause systems biology approaches and synthetic engineering of microbes are now high-throughput and cost-effective, a much wider range of therapeutic possibilities can be explored and vetted.\u003c\/p\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"ASM Press","offers":[{"title":"Default Title","offer_id":47988863402213,"sku":"NP9781555819699","price":123.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781555819699.jpg?v=1761781824","url":"https:\/\/k12savings.com\/es\/products\/bugs-as-drugs-isbn-9781555819699","provider":"K12savings","version":"1.0","type":"link"}